Ceritinib in ALK-rearranged non-small-cell lung cancer
- PMID: 24670165
- PMCID: PMC4079055
- DOI: 10.1056/NEJMoa1311107
Ceritinib in ALK-rearranged non-small-cell lung cancer
Abstract
Background: Non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in preclinical studies.
Methods: In this phase 1 study, we administered oral ceritinib in doses of 50 to 750 mg once daily to patients with advanced cancers harboring genetic alterations in ALK. In an expansion phase of the study, patients received the maximum tolerated dose. Patients were assessed to determine the safety, pharmacokinetic properties, and antitumor activity of ceritinib. Tumor biopsies were performed before ceritinib treatment to identify resistance mutations in ALK in a group of patients with NSCLC who had had disease progression during treatment with crizotinib.
Results: A total of 59 patients were enrolled in the dose-escalation phase. The maximum tolerated dose of ceritinib was 750 mg once daily; dose-limiting toxic events included diarrhea, vomiting, dehydration, elevated aminotransferase levels, and hypophosphatemia. This phase was followed by an expansion phase, in which an additional 71 patients were treated, for a total of 130 patients overall. Among 114 patients with NSCLC who received at least 400 mg of ceritinib per day, the overall response rate was 58% (95% confidence interval [CI], 48 to 67). Among 80 patients who had received crizotinib previously, the response rate was 56% (95% CI, 45 to 67). Responses were observed in patients with various resistance mutations in ALK and in patients without detectable mutations. Among patients with NSCLC who received at least 400 mg of ceritinib per day, the median progression-free survival was 7.0 months (95% CI, 5.6 to 9.5).
Conclusions: Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK. (Funded by Novartis Pharmaceuticals and others; ClinicalTrials.gov number, NCT01283516.).
Figures
Comment in
-
Overcoming drug resistance in ALK-rearranged lung cancer.N Engl J Med. 2014 Mar 27;370(13):1250-1. doi: 10.1056/NEJMe1316173. N Engl J Med. 2014. PMID: 24670172 No abstract available.
-
Ceritinib in ALK-rearranged non-small-cell lung cancer.N Engl J Med. 2014 Jun 26;370(26):2537-9. doi: 10.1056/NEJMc1404894. N Engl J Med. 2014. PMID: 24963575 No abstract available.
-
Ceritinib in ALK-rearranged non-small-cell lung cancer.N Engl J Med. 2014 Jun 26;370(26):2537. doi: 10.1056/NEJMc1404894. N Engl J Med. 2014. PMID: 24963576 No abstract available.
Similar articles
-
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11. Lancet Oncol. 2016. PMID: 26973324 Free PMC article. Clinical Trial.
-
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.J Thorac Oncol. 2015 Jul;10(7):1058-66. doi: 10.1097/JTO.0000000000000566. J Thorac Oncol. 2015. PMID: 26020125 Free PMC article. Clinical Trial.
-
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9. Lancet Oncol. 2017. PMID: 28602779 Clinical Trial.
-
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.Lung Cancer. 2017 Sep;111:51-58. doi: 10.1016/j.lungcan.2017.06.004. Epub 2017 Jun 9. Lung Cancer. 2017. PMID: 28838397 Review.
-
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Drug Des Devel Ther. 2017 Jul 5;11:2047-2063. doi: 10.2147/DDDT.S113500. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28740365 Free PMC article. Review.
Cited by
-
Mitochondria of T Lymphocytes Promote Anti-Pulmonary Tumor Immune Response.World J Oncol. 2024 Jun;15(3):472-481. doi: 10.14740/wjon1841. Epub 2024 Apr 15. World J Oncol. 2024. PMID: 38751696 Free PMC article.
-
Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer Med. 2024 Apr;13(8):e7201. doi: 10.1002/cam4.7201. Cancer Med. 2024. PMID: 38629293 Free PMC article. Review.
-
Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer.J Enzyme Inhib Med Chem. 2024 Dec;39(1):2318645. doi: 10.1080/14756366.2024.2318645. Epub 2024 Mar 11. J Enzyme Inhib Med Chem. 2024. PMID: 38465731 Free PMC article.
-
Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.Front Public Health. 2024 Feb 15;12:1213318. doi: 10.3389/fpubh.2024.1213318. eCollection 2024. Front Public Health. 2024. PMID: 38435286 Free PMC article.
-
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.Cancer Commun (Lond). 2024 Apr;44(4):455-468. doi: 10.1002/cac2.12524. Epub 2024 Feb 29. Cancer Commun (Lond). 2024. PMID: 38421881 Free PMC article. Clinical Trial.
References
-
- Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol. 2011;47:R11–R23. - PubMed
-
- Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13–17. - PubMed
-
- Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723–1733. - PubMed
-
- Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional upregulation in non-small cell lung carcinomas. Hum Pathol. 2009;40:1152–1158. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical